Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 7 of 7 for “"BRAF inhibitors"”.
-
Overcoming Acquired Resistance to BRAF Inhibitors by Novel Synergistic Drug Combination and Discovery of Novel Smac Mimetics as Selective Survivin Inhibitors
… clinical resistance to vemurafenib, a selective BRAFV600E inhibitor, arises frequently after short term chemotherapy. Since the inhibitions of targets in the RAFMEK-ERK pathway result in G0/G1 cell cycle arrest, vemurafenib-resistant cancer cells are expected to escape this cell cycle arrest and …
-
Epigenetic Modulation In Braf Mutated Metastatic Colorectal Cancer
<p><strong>Introduction:</strong> BRAF V600E mutations are associated with poor clinical outcomes for patients with metastatic colorectal cancer (mCRC). Unlike other tumors with the same mutation, BRAF inhibitors are ineffective as monotherapy. CRC tumors with BRAF V600E mutations are associated …
-
Functional assessment of BRAF and CRAF through Base Editor 3 mutagenesis reveals residues and regions critical for ERK1/2 signalling
… RASopathies. Therapeutic targeting of class I BRAF mutants has proven successful but BRAF inhibitors have failed in cancers with wild type RAF because sub-saturating doses of inhibitors drive paradoxical activation of wild-type RAF. Base editor 3 (BE3) is a gene editing tool comprised of a …
-
The role of the PD-1 pathway in the tumor microenvironment
… therapy targeted at tumor cells themselves, BRAF inhibitors. This work provided support for ongoing clinical trials. In the second section, we show that tumor cells can protect themselves from immune eradication by expressing PD-L1, which directly suppresses the cytotoxicity of CD8* T cells. …
-
Advancing T Cell–Based Immunotherapies: Identification of Tumor-Specific T Cell Receptor Targets and Mechanisms of Resistance in Solid Tumors
… months. Although 30-40% of the patients harbor BRAF mutations, which are initially responsive to BRAF inhibitors, most eventually develop resistance and relapse. Patients with resistant disease or lacking BRAF mutations have limited treatment options, highlighting the urgent need for novel …
-
Transient Metabolic Alterations Induced by Chemotherapeutics in Cancer Persisters
… melanoma cells mediated by Vemurafenib (VEM), a BRAF inhibitor. Co-treatment with BRAF inhibitors is a common treatment strategy for melanoma cancer. However, how a BRAF inhibitor itself alters melanoma cell metabolism and mediates persister survival is not well understood. Our findings …
-
An investigation on role of the ATP-binding cassette B5 (ABCB5) transporter as potential mediator of melanoma resistance to BRAF inhibition
… deaths. Targeted therapies, in the form of BRAF inhibitors (BRAFis), have been effective at treating BRAFV600 mutant melanomas. However, majority of the melanoma patients fail to respond to BRAFis due to intrinsic or acquired resistance within one year of treatment commencement. Multiple …